NATAN DAVID 4

What Happened

• Natan David, a director of Indaptus Therapeutics, was granted options to purchase 25,000 shares of common stock (reported as a derivative award) on January 7, 2026. The filing reports an acquisition price of $0.00 for the grant (i.e., no cash paid at grant).

Key Details

• Transaction type: Award/Grant of derivative securities (code A).
• Transaction date: 2026-01-07; Form 4 filed: 2026-01-22 (filed late — 15 days after the transaction).
• Shares/options granted: 25,000 options (reported as acquisition of derivative securities).
• Price reported at grant: $0.00 (no immediate cash outlay reported). Exercise price, if any, is not disclosed in the Form 4.
• Shares owned after transaction: Not disclosed in the filing.
• Footnote: Options vest over three years beginning at the grant date, in equal quarterly installments, subject to continued board service (non-employee director compensation program).

Context

• This is a standard non-employee director compensation award (options), not an open-market purchase or sale of common stock. Such grants are typically intended as long-term compensation and vest over time; they do not indicate an immediate purchase or sale of shares. The late filing reduces near-term transparency but does not change the nature of the award.